within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR22_EmtricitabineTenofovirAlafenamideDarunavirAndCobicistat;
model EmtricitabineTenofovirAlafenamideDarunavirAndCobicistat 
   extends Pharmacolibrary.Drugs.ATC.J.J05AR22;

  annotation(Documentation(
    info ="<html><body><p>Emtricitabine, tenofovir alafenamide, darunavir, and cobicistat is a fixed-dose combination antiretroviral medication used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents. The combination includes two nucleoside reverse transcriptase inhibitors (emtricitabine, tenofovir alafenamide), a protease inhibitor (darunavir), and a pharmacokinetic enhancer (cobicistat). The medicine is approved for use, commonly marketed in fixed-dose combinations, such as Symtuza.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on available published information for each constituent in healthy adult subjects after oral administration in the fixed-dose combination. Specific published pharmacokinetic models for the combination product are not available.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end EmtricitabineTenofovirAlafenamideDarunavirAndCobicistat;
